Inventor · disambiguated record
Zuwen Zhou
Also filed as: ZHOU ZUWEN
12 granted patents·5 pending applications·13 citations·filing 2014–2021
83Inventor score
Files withFOCHON PHARMACEUTICALS LTD7SHANGHAI FOCHON PHARMACEUTICAL CO LTD7FOCHON BIOSCIENCES LTD2CHONGQING FOCHON PHARMACEUTICAL CO LTD1
Top patents by PatentIndex Score
17 records- 0187US11053239B2Compounds as BLC-2-selective apoptosis-inducing agentsFOCHON PHARMACEUTICALS LTD·Filed 2018·Granted Jul 6, 2021·6 cites·13 claims
- 0278US11091478B2Apoptosis-inducing agentsFOCHON PHARMACEUTICALS LTD·Filed 2018·Granted Aug 17, 2021·2 cites·32 claims
- 0377US9714235B2Quinazoline derivatives, compositions thereof, and use as pharmaceuticalsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2014·Granted Jul 25, 2017·3 cites·2 claims
- 0471US9556171B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2014·Granted Jan 31, 2017·2 cites·15 claims
- 0560US12312349B2Apoptosis-inducing agentsFOCHON PHARMACEUTICALS LTD·Filed 2021·Granted May 27, 2025·0 cites·16 claims
- 0651US2023159527A1Compounds as bcl-2 inhibitorsFOCHON PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 0749US2022354860A1Heterocyclic derivatives and use thereofFOCHON PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 0848US2023174556A1Compounds as protein kinase inhibitorsFOCHON BIOSCIENCES LTD·Filed 2021·Application pending·0 cites
- 0947US10053449B2Quinazoline derivatives, compositions thereof, and use as pharmaceuticalsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2017·Granted Aug 21, 2018·0 cites·3 claims
- 1046US10835535B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 17, 2020·0 cites·17 claims
- 1145US10022374B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2016·Granted Jul 17, 2018·0 cites·13 claims
- 1245US2022235049A1SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORSFOCHON PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1340US2022041588A1Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitorsFOCHON PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 1436US11459332B2Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitorsFOCHON BIOSCIENCES LTD·Filed 2019·Granted Oct 4, 2022·0 cites·22 claims
- 1536US10894038B2Indolizine derivatives, composition and methods of useSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2016·Granted Jan 19, 2021·0 cites·20 claims
- 1634US10450316B2Certain protein kinase inhibitorCHONGQING FOCHON PHARMACEUTICAL CO LTD·Filed 2016·Granted Oct 22, 2019·0 cites·16 claims
- 1733US10328060B2Certain protein kinase inhibitorsSHANGHAI FOCHON PHARMACEUTICAL CO LTD·Filed 2015·Granted Jun 25, 2019·0 cites·15 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →